Posted in Clinical Data Revolution rockets on strong pancreatic cancer data April 14, 2026 Pharmaphorum Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib. Clinical DataOncologyRead full story